Takeda's TYK2 rival tops Sotyktu in psoriasis trial, eyeing 2027 launch
Takeda's TYK2 inhibitor zasocitinib beat Bristol Myers Squibb's Sotyktu in a Phase 3 head-to-head for moderate-to-severe plaque psoriasis, delivering PASI 100 in over 35% of patients at Week 16 and outperforming on key secondary endpoints with a favorable safety profile; Takeda plans a first-half 2027 launch, signaling continued pressure on Sotyktu as its sales have underperformed since its 2022 approval.